Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer

Future Oncology

Volumn 11, Issue 22, 2015, Pages 3091-3098

  De Cobelli, Ottavio ^a,b   Buonerba, Carlo ^c   Terracciano, Daniela ^d   Bottero, Danilo ^a   Lucarelli, Giuseppe ^e   Bove, Pierluigi ^f   Altieri, Vincenzo ^g   Coman, Ioman ^b   Perdonà, Sisto ^h   Facchini, Gaetano ^h   Berretta, Massimiliano ⁱ   Di Lorenzo, Giuseppe ^c   Grieco, Paolo ^d   Novellino, Ettore ^d   Franco, Renato ^h   Caraglia, Michele ^j   Manini, Claudia ^k   Mirone, Vincenzo ^d   De Placido, Sabino ^c   Sonpavde, Guru ^l   Ferro, Matteo ^a   more..

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g UNIVERSITY OF SALERNO   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j SECOND UNIVERSITY OF NAPLES   (Italy)

^k S GIOVANNI BOSCO HOSPITAL   (Italy)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

Gleason score; prostate cancer; urotensin II receptor

Indexed keywords

FORMALDEHYDE; PARAFFIN; UROTENSIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; UTS2R PROTEIN, HUMAN;

ADULT; AGED; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; GENE EXPRESSION; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; REVIEW; TUMOR BIOPSY; BIOPSY; DISEASE COURSE; GENETICS; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS;

AGED; BIOPSY; DISEASE PROGRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RETROSPECTIVE STUDIES;

EID: 84946848874     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.249     Document Type: Review

References (24)

1. Tao ZQ, Shi AM, Wang KX, Zhang WD. Epidemiology of prostate cancer: current status. Eur. Rev. Med. Pharmacol. Sci. 19(5), 805-812 (2015).
2. Klotz L, Vesprini D, Sethukavalan P et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33(3), 272-277 (2015).
3. Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF. Radical prostatectomy for locally advanced prostate cancer: current status. Urology 86(1), 10-15 (2015).
4. Tran E, Paquette M, Pickles T et al. Population-based validation of a policy change to use long-term androgen deprivation therapy for cT3-4 prostate cancer: impact of the EORTC22863 and RTOG 85-31 and 92-02 trials. Radiother. Oncol. 107, 366-371 (2013).
5. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969-974 (1998).
6. Eifler JB, Feng Z, Lin BM et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 111, 22-29 (2013).
7. Winter A, Kneib T, Rohde M, Henke RP, Wawroschek F. First nomogram predicting the probability of lymph node involvement in prostate cancer patients undergoing radioisotope guided sentinel lymph node dissection. Urol. Int. doi:10. 1159/000431182 (2015) (Epub ahead of print).
8. Buonerba C, Pond GR, Sonpavde G et al. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol. 9(6), 889-897 (2013).
9. van Soest RJ, de Morrée, ES, Shen L, Tannock IF, Eisenberger MA, de Wit R. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur. Urol. 66(2), 330-336 (2014).
10. Caster JM, Falchook AD, Hendrix LH, Chen RC. Risk of pathologic upgrading or locally advanced disease in early prostate cancer patients based on biopsy Gleason score and PSA: a population-based study of modern patients. Int. J. Radiat. Oncol. Biol. Phys. 92(2), 244-251 (2015).
11. Chun FK, Steuber T, Erbersdobler A et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur. Urol. 49(5), 820-826 (2006).
12. Terracciano D, Bruzzese D, Ferro M et al. Preoperative insulin-like growth factorbinding protein-3 (IGFBP-3) blood level predicts Gleason sum upgrading. Prostate 72(1), 100-107 (2012).
13. Oh JJ, Park S, Lee SE et al. The use of exome genotyping to predict pathological Gleason score upgrading after radical prostatectomy in low-risk prostate cancer patients. PLoS ONE 9(8), e104146 (2014).
14. Takahashi K, Totsune K, Murakami O et al. Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides 24, 301-306 (2003).
15. Grieco P, Franco R, Bozzuto G et al. Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. J. Cell Biochem. 112(1), 341-353 (2011).
16. Corcoran NM, Hong MK, Casey RG et al. Upgrading in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int. 108, E202-E210 (2011).
17. Muralidhar V, Dinh KT, Mahal BA et al. Differential post-prostatectomy cancerspecific survival of occult T3 vs. clinical T3 prostate cancer: implications for managing patients upstaged on prostate magnetic resonance imaging. Urol. Oncol. 33(7), 330. e19-25 (2015).
18. Jain S, Loblaw A, Vesprini D et al. Gleason upgrading with time in a large prostate cancer active surveillance cohort. J. Urol. 194(1), 79-84 (2015).
19. Truong M, Slezak JA, Lin CP et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer 119(22), 3992-4002 (2013).
20. Hwang I, Lim D, Jeong YB et al. Upgrading and upstaging of low-risk prostate cancer among Korean patients: a multicenter study. Asian J. Androl. 17(5), 811-814 (2014).
21. Balakan O, Kalender ME, Suner A et al. The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med. Sci. Monit. 20, 1419-1425 (2014).
22. Franco R, Zappavigna S, Gigantino V et al. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/ invasion. J. Exp. Clin. Cancer Res. 33(1), 48 (2014).
23. Chen W, Mao K, Liu Z, Dinh-Xuan AT. The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (review). Oncol. Lett. 8(5), 1907-1911 (2014).
24. Hegde JV, Chen MH, Mulkern RV, Fennessy FM, D'Amico AV, Tempany CM. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 85(2), e101-e107 (2013).